Listing of Claims:

1. (Currently Amended) A compound or compounds of formula I



I

wherein

R^6, R^7 are independently selected from one another and are H, A or SO_2A, wherein, in the case of R^6 and R^7, A is alkyl,

~~A is independently selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,~~

Ar^2 is phenyl, pyridinyl or pyrimidyl, ~~selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from the group consisting of N, O and S,~~

R^{10} is selected from the group consisting of alkyl comprising 1 to 4 carbon atoms, alkoxy comprising 1 to 4 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, perhaloalkyl comprising 1 to 4 carbon atoms, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}NR^{12}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$,

$(CH_2)_nSO_2NR^{11}R^{12}$ and $(CH_2)_nS(O)_qR^{13}$,

k is 0, 1 or 2,

r is 0, 1 or 2

R^8, and R^9 ~~and R^{10}~~ are independently selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, and $(CH_2)_nCN$,

wherein, in the case of R^8 and R^{10}, A is independently selected from the group consisting alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy and alkoxyalkyl,

~~$(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nOR^{11}$, $(CH_2)_nO(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nCOOR^{12}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{12}$, $(CH_2)_nNR^{11}CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_qR^{13}$, $(CH_2)_nOC(O)R^{12}$, $(CH_2)_nCOR^{12}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{12})HCOOR^{12}$, $C(R^{12})HCOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^{12}$, $(CH_2)_nN(R^{11})CH_2CH_2NR^{11}R^{12}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2NR^{11}R^{12}$, CH=$CHCH_2OR^{12}$, $(CH_2)_nN(COOR^{11})COOR^{12}$, $(CH_2)_nN(CONH_2)COOR^{11}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{11})COOR^{12}$, $(CH_2)_nN(CH_2CONH_2)COOR^{11}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{12}COR^{11}$, $(CH_2)_nCHR^{12}COOR^{11}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$;~~ wherein

a

R^{11}, R^{12} are independently selected from the group consisting of H, A,

$(CH_2)_mAr^3$ and $(CH_2)_mHet$, or in $NR^{11}R^{12}$,

R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7-membered heterocycle which optionally contains 1 or 2 additional heteroatoms, selected from the group consisting of N, O and S,

R^{13}, ~~R^{14}~~ ~~are independently~~ is selected from the group consisting of H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_mHet$,

Ar^3, Ar^4 are independently selected from one another and are aromatic hydrocarbon residues comprising 5 to 12 carbon atoms which are optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from the group consisting of A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from the group consisting of H, A, and $(CH_2)_mAr^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

k, m and n are independently selected from ~~of~~ one another and are 0, 1, 2, 3, 4, or 5,

X is selected from the group consisting of O, S, N-R^{21}, CH_2, CH_2CH_2, OCH_2, and CH_2O, ~~represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_h$-Q-$(CHR^{12})_i$, wherein~~

~~Q is selected from the group consisting of O, S, N-R^{15}, $(CHal_2)_j$, $(O\text{-}CHR^{18})_j$, $(CHR^{18}\text{-}O)_j$, $CR^{18}{=}CR^{19}$, $(O\text{-}CHR^{18}CHR^{19})_j$, $(CHR^{18}CHR^{19}\text{-}O)_j$, C=O, C=S, C=$NR^{15}$, $CH(OR^{15})$, $C(OR^{15})(OR^{20})$, C(=O)O, OC(=O), OC(=O)O, C(=O)N(R^{15}), N(R^{15})C(=O), OC(=O)N(R^{15}), N(R^{15})C(=O)O, CH=N-O, CH=N-NR^{15}, S=O, SO_2, SO_2NR^{15} and $NR^{15}SO_2$, wherein~~

~~R^{18}, R^{19}, R^{20} are independently selected from the group consisting of the meanings given for R^8, R^9 and R^{10};~~

~~h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, and~~

~~j is 1, 2, 3, 4, 5, or 6,~~

Y is selected from the group consisting of O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$, wherein

R^{21} ~~is independently selected from~~ has the meanings given for R^{13}, ~~R^{14} and~~

R^{22} ~~is independently selected from~~ has the meanings given for R^{11}, or R^{12},

p, r ~~are~~ is ~~independently from one another~~ 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4,

u is 0, 1, 2 or 3,

and

Hal is independently selected from the group consisting of F, Cl, Br and I; or

tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers thereof or mixtures thereof in all ratios.

2. (Canceled)

3. (Currently Amended) The compound or compounds according to claim 1, selected from the group consisting of the compounds of formulae Ia, Ib, Ic and Id,



Ia



Ib



Ic



Id

wherein

R^8, p, X, Y, R^9 and q are as defined in claim 1, and R^{10} is H or as defined in claim 1,

or tautomeric forms thereof, pharmaceutically acceptable derivatives, solvates, salts and stereoisomers thereof or mixtures thereof in all ratios.

4. (Canceled)

5. (Currently amended) The compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts,

stereoisomers or mixtures thereof in all ratios, ~~selected from the group consisting of compounds (1) to (128) of table 1;~~ having formula A-CO-NH-B, wherein A- and -B are selected from the group consisting of ~~tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers and mixtures thereof in all ratios~~

	A-	-B
(1)		
(2)		
(3)		
(4)		
(5)		

(6)		
(7)		
(8)		
(9)		
(10)		
(11)		
(12)		

(13)		
(14)		
(15)		
(16)		
(17)		
(18)		
(19)		
(20)		

(21)  

(22)  

(23)  

(24)  

(25)  

(26)  

(27)  

(28)  

(29)  

(30)  

(31)  

(32)  

(33)  

(34)  

(35)  

(36)  

(37)  

(38)  

(39)  

(40) 

(41) 

(42) 

(43) 

(44) 

(45) 

(46) 

(47)		
(48)		
(49)		
(50)		
(51)		
(52)		

(53)		
(54)		
(55)		
(56)		
(57)		
(58)		

(59)  

(60)  

(61)  

(62)  

(63)  

(64)  

(65)



(66)

(67)

(68)

(69)

(70)





(71)





(72)





(73)





(74)





(75)





(76) 

(77) 

(78) 

(79) 

(80) 

(81) 

(82) 

(83)		
(84)		
(85)		
(86)		
(87)		
(88)		

(89)		
(90)		
(91)		
(92)		
(93)		
(94)		

(95)		
(96)		
(97)		
(98)		
(99)		
(100)		
(101)		

(102)		
(103)		
(104)		
(105)		
(106)		
(107)		

(108)  

(109)  

(110)  

(111)  

(112)  

(113)  

(114) 

(115) 

(116) 

(117) 

(118) 

(119) 

(120) 

(121) 

(122) 

(123) 

(124) 

(125) 

(126) 

(127) 

(128) 

6. (Currently Amended) The compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, as a medicament.

7. (Currently Amended) The compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, as a kinase inhibitor.

8. (Previously presented) The compound or compounds according to claim 7, characterized in that the kinases are selected from the group consisting of raf-kinases and VEGFR kinases.

9. (Currently Amended) A pharmaceutical composition, comprising one or more of the compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios.

10. (Previously presented) The pharmaceutical composition according to claim 9, characterized in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients.

11. (Currently Amended) A process for the manufacture of a pharmaceutical composition, comprising that one or more of the compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, and one or more compound or compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compound or compounds according to claim 1, is processed by mechanical means into a pharmaceutical composition that is suitable as dosage form for application and/or administration to a patient.

12. (Withdrawn, currently amended) A method comprising administering to a patient the compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, as a pharmaceutical.

13. (Withdrawn, currently amended) A method comprising administering to a patient the compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, in the treatment and/or prophylaxis of a disorder or disorders.

14. (Canceled)

15. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are caused, mediated and/or propagated by kinases selected from the group consisting of raf-kinases and VEGFR kinases.

16. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

17. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders is cancer.

18. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders is noncancerous.

19. (Withdrawn) The method of claim 18, characterized in that the noncancerous disorder or disorders are selected from the group consisting of infections, psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological disease, autoimmune disease and immunodeficiency disease.

20. (Withdrawn, currently amended) The method of claim 17, characterized in that the cancer is ~~disorder or disorders are~~ selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

21. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation and neurodegenerative disease.

22. (Withdrawn) The method of claim 13, characterized in that the disorder or disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.

23. (Withdrawn, currently amended) A method of treatment comprising administering to a patient the compound or compounds according to claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixtures thereof in all ratios, as a kinase inhibitor.

24. (Withdrawn) The method of claim 23, characterized in that the kinase is one or more raf-kinases, selected from the group consisting of A-Raf, B-Raf and Raf-1.

25. (Withdrawn) The method of claim 13, characterized in that one or more of the compound or compounds is administered to a patient in need of such a treatment.

26. (Withdrawn) The method of claim 25, characterized in that one or more of the compound or compounds are administered to the patient as a pharmaceutical composition.

27. (Withdrawn) The method of claim 26, characterized in that the disorder or disorders are caused, mediated and/or propagated by kinases selected from the group consisting of raf-kinases and VEGFR kinases.

28. (Withdrawn) The method of claim 17, characterized in that the disorder or disorders is cancerous cell growth mediated by one or more kinases.

29. (Withdrawn, currently amended) A method for producing the compound or compounds of claim 1, or tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers thereof, comprising that

a) a compound of formula II



II

wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6, R^8, p and Y are as defined in claim 1,

is reacted

b) with a compound of formula III,



III

wherein

L^2 is H or a metal ion, and R^7, R^9, q, X, Ar^2, R^{10} and r are as defined in

claim 1,

and optionally

c) isolating and/or treating the compound or compounds of claim 1 obtained by said reaction with an acid, to obtain the salt thereof.

30. (Withdrawn) A compound or compounds of formula II,



II

wherein

L^1 is Cl, Br, I, OH, an esterified OH-group or a diazonium moiety, and R^6, R^8, p and Y are as defined in claim 1.

31. (Withdrawn) A compound or compounds of formula III,



III

wherein

L^2 is H or a metal ion, and R^7, R^9, q, X, Ar^2, R^{10} and r are as defined in claim 1.

32. (New) The compound or compounds according to claim 1, wherein

R^6 and R^7 are independently from one another H or alkyl, wherein alkyl is a unbranched or branched alkyl residue comprising 1 to 6 carbon atoms, optionally optionally substituted by one or more halogen atoms, by one or more hydroxy groups or by one or more amino groups which can optionally be substituted by alkyl comprising 1 to 6 carbon atoms,

Ar^2 is pyridinyl or pyrimidyl,

R^8 is independently selected from the group consiting of H, hal, unbranched or branched alkyl residues comprising 1 to 6 carbon atoms, optionally substituted by one or more halogen atoms, by one or more hydroxy groups or by one or more amino groups which can optionally be substituted by alkyl comprising 1 to 6 carbon atoms, and
unbranched or branched alkoxy residues comprising 1 to 6 carbon atoms, optionally substituted by one or more halogen atoms, by one or more hydroxy groups or by one or more amino groups which can optionally be substituted by alkyl comprising 1 to 6 carbon atoms,

R^9 is independently selected from the group consisting of H, hal, and unbranched or branched alkyl residues comprising 1 to 6 carbon atoms, optionally substituted by one or more halogen atoms, by one or more hydroxy groups or by one or more amino groups which can optionally be substituted by alkyl comprising 1 to 6 carbon atoms,

R^{10} is independently selected from the group consisting of H, alkyl comprising 1 to 4 carbon atoms, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCOOR^{13}$ and $(CH_2)_nCONR^{11}R^{12}$,

X is selected from the group consisting of O, S and CH_2, and

Y is selected from the group consisting O, S and NR^{21},

tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixture thereof in all ratios..

33. (New) The compound or compounds according to claim 1, wherein

R^6 and R^7 are independently from one another H or alkyl, wherein alkyl is selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, tert.-butyl, 2-amino ethyl, N-methyl-2-amino ethyl, N,N-dimethyl-2-amino ethyl, N-ethyl-2-amino ethyl, N,N-diethyl-2-amino ethyl, 2-hydroxy ethyl, 2-methoxy ethyl and 2-ethoxy ethyl,

Ar^2 is pyridinyl or pyrimidyl,

R^8 is independently selected from the group consiting of H, hal, alkyl residues selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, tert.-butyl, 2-amino ethyl, N-methyl-2-amino ethyl, N,N-dimethyl-2-amino

ethyl, N-ethyl-2-amino ethyl, N,N-diethyl-2-amino ethyl, 2-hydroxy ethyl, 2-methoxy ethyl and 2-ethoxy ethyl, and alkoxy residues selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, 2-butoxy, tert.-butoxy and perhalogenated derivatives thereof selected from the group consisting of O-CCl_3, O-CF_3, O-C_2Cl_5, O-C_2F_5, O-$C(CCl_3)_3$ and O-$C(CF_3)_3$,

R^9 is independently selected from the group consisting of H, hal, and alkyl, wherein alkyl is selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, tert.-butyl, 2-amino ethyl, N-methyl-2-amino ethyl, N,N-dimethyl-2-amino ethyl, N-ethyl-2-amino ethyl, N,N-diethyl-2-amino ethyl, 2-hydroxy ethyl, 2-methoxy ethyl and 2-ethoxy ethyl,

R^{10} is independently selected from the group consisting of H, alkyl comprising 1 to 4 carbon atoms, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCOOR^{13}$ and $(CH_2)_nCONR^{11}R^{12}$, wherein

R^{11}, R^{12} and R^{13} are independently selected from a group consisting of H and alkyl, wherein alkyl is selected from the group consisting of methyl, ethyl, trifluoro methyl, pentafluoro ethyl, isopropyl, tert.-butyl, 2-amino ethyl, N-methyl-2-amino ethyl, N,N-dimethyl-2-amino ethyl, N-ethyl-2-amino ethyl, N,N-diethyl-2-amino ethyl, 2-hydroxy ethyl, 2-methoxy ethyl and 2-ethoxy ethyl,

hal is independantly selected from F, Cl and Br,

X is selected from the group consisting of O, S and CH_2, and

Y is selected from the group consisting O and S, or

tautomeric forms, pharmaceutically acceptable derivatives, solvates, salts, stereoisomers or mixture thereof in all ratios.